---
description: Harvard and MIT-developed AI clinical decision support tool handles 8.5M consultations per month and scored 100 percent on USMLE with valuation surging from 3.5B to 12B in six months signaling that physicians will adopt AI tools that fit existing workflows
type: claim
domain: health
created: 2026-02-17
source: "OpenEvidence announcements 2025-2026; CNBC January 2026; Sutter Health integration February 2026"
confidence: likely
related_claims:
  - generative-ai-medical-devices-require-new-regulatory-frameworks-because-non-determinism-continuous-updates-and-inherent-hallucination-are-architectural-properties
  - medical-benchmark-performance-does-not-predict-clinical-safety-as-usmle-scores-correlate-only-0-61-with-harm-rates
sourced_from:
- inbox/archive/health/2026-03-22-openevidence-sutter-health-epic-integration.md
---

# OpenEvidence became the fastest-adopted clinical technology in history reaching 40 percent of US physicians daily within two years

OpenEvidence is the breakout story in clinical AI. Developed by Harvard and MIT researchers, it operates across 10,000+ hospitals, handles 8.5 million clinical consultations per month, and was the first AI to score 100% on the USMLE. Strategic content partnerships with NEJM and JAMA ground its responses in peer-reviewed evidence.

The valuation trajectory reflects market conviction: $3.5B (Series B, July 2025) → $6.1B (October 2025) → $12B (Series D, January 2026, co-led by Thrive Capital and DST Global). In February 2026, Sutter Health announced integration directly into Epic workflows, signaling the shift from standalone tools to EHR-embedded clinical decision support.

What makes this significant is the adoption speed. Reaching 40% of US physicians in ~2 years is unprecedented for any clinical technology. The lesson: physicians adopt AI tools that (1) answer clinical questions faster than existing alternatives, (2) cite verifiable evidence, and (3) fit into existing workflows rather than requiring new ones. OpenEvidence succeeded where previous clinical AI failed because it treated the physician as the user, not the patient.

The incumbent response is UpToDate ExpertAI (Wolters Kluwer, Q4 2025), leveraging its trusted brand and install base. The competitive dynamic -- startup vs incumbent in clinical decision support -- will determine whether AI clinical knowledge becomes a winner-take-all market or fragments.


### Additional Evidence (extend)
*Source: [[2026-01-01-openevidence-clinical-ai-growth-12b-valuation]] | Added: 2026-03-18*

OpenEvidence scale as of January 2026: 20M clinical consultations/month (up from 8.5M in 2025, representing 2,000%+ YoY growth), valuation increased from $3.5B to $12B in months, reached 1M consultations in a single day (March 10, 2026 milestone), used across 10,000+ hospitals. First AI to score 100% on all parts of USMLE. Despite this scale, 44% of physicians remain concerned about accuracy/misinformation and 19% about lack of oversight/explainability—trust barriers persist even among heavy users.


### Additional Evidence (extend)
*Source: [[2026-03-20-openevidence-1m-daily-consultations-milestone]] | Added: 2026-03-20*

OpenEvidence reached 1 million clinical consultations in a single 24-hour period on March 10, 2026, representing a 30M+/month run rate—50% above their previous 20M/month benchmark. CEO Daniel Nadler claims 'OpenEvidence is used by more American doctors than all other AIs in the world—combined.' Institutional adoption expanded with Sutter Health collaboration to integrate OE into physician workflows.

---

### Additional Evidence (extend)
*Source: [[2026-03-21-openevidence-12b-valuation-nct07199231-outcomes-gap]] | Added: 2026-03-21*

OpenEvidence reached 30M+ monthly consultations by March 2026, including a historic milestone of 1 million consultations in a single day on March 10, 2026. The company projects 'more than 100 million Americans will be treated by a clinician using OpenEvidence this year.' This represents continued exponential growth from the 18M monthly consultations reported in December 2025.

### Additional Evidence (challenge)
*Source: [[2026-03-22-arise-state-of-clinical-ai-2026]] | Added: 2026-03-22*

ARISE report reframes OpenEvidence adoption as shadow-IT workaround behavior rather than validation of clinical value. Clinicians use OE to 'bypass slow internal IT systems' because institutional tools are too slow for clinical workflows. This suggests rapid adoption reflects institutional system failure, not OE's clinical superiority.

### Additional Evidence (extend)
*Source: [[2026-03-22-openevidence-sutter-health-epic-integration]] | Added: 2026-03-22*

Sutter Health (3.3M patients, ~12,000 physicians) integrated OpenEvidence into Epic EHR workflows in February 2026, marking the first major health-system-wide EHR embedding. This shifts OpenEvidence from standalone app to in-workflow clinical tool, institutionalizing what ARISE identified as physicians bypassing institutional IT governance.

### Additional Evidence (extend)
*Source: [[2026-03-20-iatrox-openevidence-uk-dtac-nice-esf-governance-review]] | Added: 2026-03-24*

iatroX reports OE has 'signalled plans for global expansion as a key 2026 and beyond initiative' with UK, Canada, Australia identified as 'English-first markets with lower regulatory barriers.' However, iatroX notes this perception may be inaccurate for UK: NHS requires DTAC + MHRA Class 1 for formal deployment. OE's characterization of UK as having 'lower regulatory barriers' relative to US may be a strategic misjudgment—UK NHS has MORE formal digital health procurement governance than US (no federal equivalent to DTAC).





Relevant Notes:
- [[centaur team performance depends on role complementarity not mere human-AI combination]] -- OpenEvidence is the clinical centaur: AI provides evidence synthesis, physician provides judgment
- [[knowledge scaling bottlenecks kill revolutionary ideas before they reach critical mass]] -- OpenEvidence solved clinical knowledge scaling by making evidence retrieval instant

Topics:
- livingip overview
- health and wellness
